The Single Nucleotide Polymorphism IVS 1 + 309 in Mouse Double Minute 2 Does Not Affect Risk of Familial Breast Cancer

The mouse double minute 2 (MDM2) oncoprotein promotes cell survival and cell cycle progression by inhibiting the p53 tumor suppressor protein. Further, MDM2 overexpression can inhibit DNA double-strand break repair in a p53-independent manner. Recently, it was shown that a single nucleotide polymorphism (SNP) in the MDM2 promoter was associated with an accelerated tumor formation in individuals with a p53 mutation. The present case-control study investigated the association of this SNP (IVS1+309) with the risk and the age of onset of familial breast cancer in patients with unknown p53 mutation status. Data from 549 women affected by familial breast cancer and 1,065 healthy controls were analyzed. The cases did not carry BRCA1/2 mutations. Cases and controls showed a similar genotype distribution and the SNP did not seem to modify the age of onset of familial breast cancer. The data were also examined taking into account the presence of any additional cancer after breast cancer and the family history of cases; however, no association was found. These results suggest that the SNP IVS1+309 alone affects neither the risk nor the age of onset of heritable breast cancer. (Cancer Res 2006; 66(2): 646-8)

[1]  D. Eccles,et al.  No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. , 2006, Cancer letters.

[2]  C. Bonaïti‐pellié,et al.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.

[3]  Sandya Liyanarachchi,et al.  p53 Codon 72 and MDM2 SNP309 Polymorphisms and Age of Colorectal Cancer Onset in Lynch Syndrome , 2005, Clinical Cancer Research.

[4]  L. Aaltonen,et al.  The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck , 2005, Journal of Medical Genetics.

[5]  A. Levine,et al.  A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. , 2005, Cancer research.

[6]  Ruiwen Zhang,et al.  p53-independent activities of MDM2 and their relevance to cancer therapy. , 2005, Current cancer drug targets.

[7]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[8]  D. Easton,et al.  EMGM Abstracts , 2003, Genetic epidemiology.

[9]  R. Wooster,et al.  Breast and ovarian cancer. , 2003, The New England journal of medicine.

[10]  J. Peto,et al.  The future of association studies of common cancers , 2003, Human Genetics.

[11]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[12]  A. Meindl,et al.  Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population , 2002, International journal of cancer.

[13]  J. Varley,et al.  Relative frequency and morphology of cancers in carriers of germline TP53 mutations , 2001, Oncogene.

[14]  W D Plummer,et al.  Power and sample size calculations for studies involving linear regression. , 1998, Controlled clinical trials.

[15]  D. Carney,et al.  Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. , 1995, British Journal of Cancer.

[16]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[17]  K. Hemminki,et al.  A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA 1 and BRCA 2 mutations , 2005 .

[18]  B. Quesnel,et al.  MDM2 gene amplification in human breast cancer. , 1994, European journal of cancer.